Leadless tissue stimulation systems and methods

• US 9,008,776 B2
• Filed: 10/22/2012
• Issued: 04/14/2015
• Est. Priority Date: 12/21/2004
• Status: Active Grant

• Current Assignee: EBR Systems, Inc.
• Original Assignee: EBR Systems, Inc.
• Inventors: Cowan, Mark W., Echt, Debra S., Riley, Richard E., Brisken, Axel F.
• Primary Examiner(s): Bertram, Eric D.
• Application Number:
  US13/657,252
• Publication Number:
  US 20130282073A1
• Time in Patent Office: 904 Days
• Field of Search: 607/10, 607/14, 607/33
• US Class Current: 607/33
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/368 comprising more than one electrode co-operating with different heart regions A61N1/3622, A61N1/3627 take precedence
• CPC Class Codes: A61N 1/37205 Microstimulators, e.g. implantable through a cannula
• CPC Class Codes: A61N 1/37217 characterised by the communication link, e.g. acoustic or tactile
• CPC Class Codes: A61N 1/3756 Casings with electrodes thereon, e.g. leadless stimulators
• CPC Class Codes: A61N 1/3787 from an external energy source

Abstract

Systems including an implantable receiver-stimulator and an implantable controller-transmitter are used for leadless electrical stimulation of body tissues. Cardiac pacing and arrhythmia control is accomplished with one or more implantable receiver-stimulators and an external or implantable controller-transmitter. Systems are implanted by testing external or implantable devices at different tissue sites, observing physiologic and device responses, and selecting sites with preferred performance for implanting the systems. In these systems, a controller-transmitter is activated at a remote tissue location to transmit/deliver acoustic energy through the body to a receiver-stimulator at a target tissue location. The receiver-stimulator converts the acoustic energy to electrical energy for electrical stimulation of the body tissue. The tissue locations(s) can be optimized by moving either or both of the controller-transmitter and the receiver-stimulator to determine the best patient and device responses.

Claims

1. A system for the delivery of antitachycardia pacing to a patient'"'"'s heart, comprising:

at least one implantable receiver-stimulator adapted to contact at least one cardiac stimulation site, wherein the receiver-stimulator is present in a sealed case; and

a subcutaneously implantable acoustic controller-transmitter, wherein the controller-transmitter is present in a separate sealed case from that of the receiver-stimulator, wherein the controller-transmitter is adapted to contain an electrogram signal processor and sensing electrodes for processing electrogram signals from the electrodes that are located on the exterior surface of the controller-transmitter and are in contact with tissue, and wherein the controller-transmitter is configured to detect a signal from a separate cardiac pacemaker,

wherein the controller-transmitter is adapted to transmit acoustic energy upon detecting the signal from a separate cardiac pacemaker and the receiver-stimulator is adapted to receive the acoustic energy and convert the acoustic energy into cardiac stimulation energy based on both energy and signal information included in the received acoustic energy.

2. A system as in claim 1, wherein the receiver-stimulator comprises one or more stimulation electrodes adapted to deliver the cardiac stimulation energy such that the stimulation electrodes lie in electrical communication with the cardiac stimulation site.

3. A system as in claim 1, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location that optimally terminates the tachyarrhythmia.

4. A system as in claim 3, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location within the tissue which is in a conduction pathway of the tachyarrhythmia.

5. A system as in claim 1, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location that optimally prevents a tachyarrhythmia.

6. A system as in claim 1, wherein the implantable receiver-stimulator is adapted to be placed and secured at a location within the tissue which is in the normal conduction pathway of the heart.

7. A system as in claim 1, where in the implantable receiver-stimulator is configured to be placed and secured at any location within a cardiac chamber.

8. A system as in claim 1, where in the implantable receiver-stimulator is configured to be placed and secured at any location within myocardial tissue.

9. A system as in claim 1, wherein the implantable receiver-stimulator is configured to be placed and secured at a location on the epicardial aspects of the heart.

10. A system as in claim 1, wherein two or more receiver-stimulators are configured to be placed and secured in locations that optimally prevent or terminate the tachyarrhythmia.

11. A system as in claim 1, wherein the controller-transmitter processes the electrocardiogram to determine the presence or absence of a tachyarrhythmia.

12. A system as in claim 11, wherein the determination of the presence or absence of a tachyarrhythmia is based on heart rate or electrogram waveform morphology.

13. A system as in claim 1, wherein the controller-transmitter is adapted to transmit acoustic energy to at least one of the receiver-stimulator(s) when tachyarrhythmia is detected.